派林生物人凝血因子IX药品注册上市许可获受理

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]